Chugai Pharmaceutical Co., Ltd. (CHGCY)
| Market Cap | 91.25B +22.0% |
| Revenue (ttm) | 8.12B +5.7% |
| Net Income | 2.84B +10.3% |
| EPS | 1.73 +10.2% |
| Shares Out | n/a |
| PE Ratio | 32.09 |
| Forward PE | n/a |
| Dividend | 1.36 (4.96%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 10,625 |
| Average Volume | 229,289 |
| Open | 27.76 |
| Previous Close | 27.88 |
| Day's Range | 27.33 - 27.78 |
| 52-Week Range | 19.50 - 34.84 |
| Beta | 0.60 |
| RSI | 47.01 |
| Earnings Date | Apr 24, 2026 |
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular... [Read more]
Financial Performance
In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.
Financial numbers in JPY Financial StatementsNews
Japanese drugmakers slump after Trump unveils discount drug website
Shares of Japanese pharmaceutical companies slumped in early Tokyo trading on Friday after U.S. President Donald Trump's website offering discounted prescription medicines went live.